牙医关于抗血栓药物的知识,态度和做法:前后测试研究
Fatıma Ulya Yürük1,2, Songül Tezcan3, Ayşenur Cengiz4
1Hamidiye Faculty of Pharmacy, Clinical Pharmacy, University of Health Sciences, Istanbul, Türkiye. ulyayuruk1995@gmail.com.
BMC medical education
|October 8, 2025
概括
临床药剂师培训显著改善了牙医对抗血栓药物的知识和态度. 这种增强的理解有助于管理这些关键药物的牙科患者的出血风险.
科学领域:
- 牙科药理学 牙科药理学
- 临床药房 临床药房
- 患者安全 患者安全
背景情况:
- 在牙科中对服用抗血栓药物的患者进行管理对于预防出血和血栓形成至关重要.
- 牙医需要更新的知识和实践,以确保安全的病人护理.
研究的目的:
- 评估临床药剂师领导的培训对牙医对抗血栓药物的理解的影响.
- 评估牙医关于抗血栓治疗的知识,态度和实践的变化.
主要方法:
- 在牙科卫生中心采用了前后测试设计.
- 一个由49项组成的问卷评估了牙医在45分钟的培训课程之前和之后的知识和态度.
- 238名牙医参与了这项研究.
主要成果:
- 牙医对抗血栓药物的基础知识很低 (13.2%),在培训后显著增加到91.7%.
- 在培训后,89.3%的牙医正确理解牙科手术时的阿司匹林管理,高于13.2%.
- 对华法林管理的理解有了显著的改善,正确反应从13.2%上升到55.6%.
结论:
- 临床药剂师培训明显提高了牙医对抗血栓药物的知识和态度.
- 更好的理解可以导致更安全的抗血栓治疗患者的牙科管理.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Coronary Artery Disease V: Interprofessional Care
215
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319


